Status and phase
Conditions
Treatments
About
This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.
Full description
Night time bedwetting is a common complication of sickle cell disease, and affects up to 30 % of children. Desmopressin is an oral medication that increases water reabsorption in the kidneys. Studies have shown that it is effective in decreasing bedwetting episodes in children without sickle cell disease. Chronic sickling episodes causing damage to the kidneys could cause permanent damage and may make this treatment ineffective in sickle cell disease. This trial will inform pediatric sickle cell doctors if desmopressin is an appropriate treatment for bed wetting in the investigators patients.
This study expanded upon a previously terminated study which had separately registered (NCT02636387, ID: 2014-3768).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
8 participants in 1 patient group
Loading...
Central trial contact
Kerry Morrone, MD; Deepa Manwani, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal